... Adult N = 38 IV N = 22 Burosumab, N = 17 Placebo, N = 5 SC, N = 16 Burosumab, N = 12 Placebo, N = 4 ...
... Burosumab: 10 (83%) Placebo: 2 (50%) AEs related to burosumab: 6 (21%) IV: 4 (24%) SC: 2 (17%) AE leading to ...
... , Pathophysiology and Pharmacology Jon Vincze 1,2 , Brian W. Skinner 3 , Katherine A. Tucker 4 , Kory A. Conaway 1,2 ...
... , Jonathan W. Lowery 1,2, * and Julia M. Hum 1,2, * 1 2 3 4 * Citation: Vincze, J ...
... osteocytes [4]. Mutation in the PHEX gene product leads to increased serum levels of FGF23. FGF23 is a potent ...